darolutamide – Page 3 – PROSTATE WARRIORS – The latest news about prostate cancer

Tag Archive for: darolutamide

FDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC

August 8, 2025/in Clinical Trial, Metastatic, Phase 1/by Max

Summary of the PC-BETS Substudy C: Darolutamide in Biomarker-Selected mCRPC

July 23, 2025/in Clinical Trial, Metastatic, Phase 2/by Max

European Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer

July 23, 2025/in FDA approvals/by Max

The European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]

Triplet therapy shows strongest survival benefit in mHSPC with visceral disease

July 14, 2025/in Review/by Max

Early Results of Gedatolisib and Darolutamide in mCRPC Treatment

July 4, 2025/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max

Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment

June 20, 2025/in Retrospective studies/by Max

A New Insight From the ARANOTE Trial for mHSPC

April 30, 2025/in Post-hoc/by Max

ASCO GU 2025: Darolutamide Triplet Therapy Outperforms Alternatives in Advanced Prostate Cancer

February 13, 2025/in Retrospective studies/by Max

Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer

January 14, 2025/in Clinical Trial, Metastatic, Phase 1/by Max

A Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer

November 6, 2024/in Clinical Trial, Metastatic, Phase 1/by Max